Structure base drug discovery company
Amura Holdings Ltd., Minerva Building, Babraham Research Campus, Babraham, CB22 3AT, U.K.
Home
Company
Technologies
Programmes
Osteoporosis
Autoimmunity
Malaria
-lactamase inhibitors (BLIs)
Bone metastasis
Chronic neuropathic pain
Osteoarthritis
Cathepsin K and Arthritic Disease
News
Contact
Sitemap
Search
 
 
     
 

Programmes

Amura's main research focus is the exploitation of the AMcore technology for the selective inhibition of CAC1 proteases. 

Amura also has exclusive commericial and intellectual property rights to a broad spectrum -lactamase inhibitors (AM-112). This is an ideal protective combination product for otherwise resistance susceptible b-lactam antibiotics.

For more information on the Amura programmes, please use the sub-menus within the navigation pane on the left.

                              

A molecular model of an Amura AMcore bicyclic inhibitor (ex WO2008007127) in the active site of cathepsin K

 

 
 
 
 
 
     
Email: amura@amura.co.uk
Phone: +44(0)1223 839797 Fax: +44(0)1223 839898 Copyright 2009 Amura Holdings Ltd.